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This seventh best-practice review examines four series of
common primary care questions in laboratory medicine: (1)
blood count abnormalities 2; (2) cardiac troponins; (3) high-
density lipoprotein cholesterol; and (4) viral diseases 2. The
review is presented in a question–answer format, with
authorship attributed for each question series. The
recommendations are a pre´cis of guidance found using a
standardised literature search of national and international
guidance notes, consensus statements, health policy documents
and evidence-based medicine reviews, supplemented by
Medline Embase searches to identify relevant primary research
documents. The recommendations are not standards, but form a
guide to be set in the clinical context. Most are consensus based
rather than evidence based. They will be updated periodically
to take account of new information.
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T
his is the seventh in a planned series of
reviews to answer a number of questions that
arise in primary care pathology.
Each topic is introduced with a brief summary of
the type of information found and is handled
separately, with authorship attributed.
Although the individual topics are not related—
they cover the disciplines of clinical biochemistry,
microbiology, immunology, haematology and cel-
lular pathology—they are designed to form a
resource that, once completed, will be indexed
and will cover a wide range of the most common
primary care laboratory issues, to be made avail-
able to users.
In instances where the new UK General Medical
Services (GMS) contracts make specific reference
to a laboratory test, the indicator or target is
appended at the end of the answer.
BLOOD COUNT ABNORMALITIES 2 (MJG,
DB, WSAS, GS, PJC)
This second series of blood count scenarios
examines selected abnormalities of white cell
counts—namely, lymphocytosis, neutropenia and
eosinophilia.
As a typical full blood count report may contain
>10 results, values outside the quoted reference
ranges occur frequently on a statistical basis. These
questions and answers attempt to establish thresh-
olds for clinical action or referral and identify
situations that are likely to be of clinical impor-
tance. Some (eg, lymphocytosis) are extensively
reviewed in existing guidelines, cited as the
primary reference sources, whereas others, such
as eosinophilia, draw guidance mostly from extra-
polation from observational studies
When should I refer an adult patient with a
lymphocytosis?
We recommend the following criteria for
referral:
N a lymphocytosis (.5.06109 cells/l), that is not
explained clinically by acute, self-limiting viral
illness.
N high lymphocyte count in patients previously
diagnosed as having stage A chronic lympho-
cytic leukaemia (CLL) and followed up in
primary care, if accompanied by anaemia and/
or thrombocytopenia.
N development of any indications for treatment in
a patient with grade A CLL being followed up in
primary care.
The primary aim of this answer is to establish
the need for referral of patients with possible
leukaemia or lymphoma. Patients may be found to
have a lymphocytosis in the course of routine
investigations for unrelated symptoms or as part of
health screening. The cause may be an increase in
T lymphocytes that is often reactive to an acute
illness and is rarely a reflection of malignancy.1
Alternatively, a B cell lymphocytosis may be
present, which may be polyclonal but more often
is the result of a clonal lymphoproliferative
disorder, usually CLL. Other conditions presenting
with a lymphocytosis, such as follicular lym-
phoma, marginal zone lymphoma, mantle-cell
lymphoma or hairy-cell leukaemia, will often have
clinical features, such as anaemia, splenomegaly or
lymphadenopathy, and the blood film appearances
may not be compatible with CLL.1 Although there
is limited clear guidance, it would seem reasonable
to wait for an acute viral illness to resolve and
recheck the lymphocyte count when a lymphocy-
tosis is associated with features of acute viral
illness.
Diagnosis
A definitive diagnosis of CLL is based on the
combination of a lymphocytosis .5.06109 cells/l
and a characteristic lymphocyte morphology and
immunophenotype. Immunophenotyping is
required to accurately classify the nature of the
Abbreviations: ACS, acute coronary syndrome; CHD,
coronary heart disease; CLL, chronic lymphocytic
leukaemia; CMV, cytomegalovirus; EBV, Epstein–Barr virus;
FBC, full blood count; GMS, General Medical Services;
HDL-C, high-density lipoprotein cholesterol; LDL-C, low-
density lipoprotein cholesterol
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lymphocyte proliferation, thus enabling an appropriate treat-
ment plan to be made. Although some morphological features
are associated with the different types of lymphocyte prolifera-
tion, these are no longer acceptable as the only means of
confirming the diagnosis that will influence the patient’s
management. Immunophenotyping is always indicated in
patients requiring treatment, in patients with lymphocytosis,
that on morphological review is not typical of CLL, and in
patients in whom it is thought important to exclude a reactive
lymphocytosis.1 Blood films should be prepared for patients
who have lymphocytosis .56109 cells/l when reviewed for the
first time.2
When should I refer a patient with lymphocytosis to a
haematologist?
Patients with lymphocytosis should be referred for a review by a
haematologist if they have lymphadenopathy, splenomegaly,
anaemia, thrombocytopenia, or when the blood film reports a
lymphocytosis that is not consistent with CLL,1 or when the
lymphocytosis is not explained clinically by an acute self-
limiting viral illness (box 1).
Clinical fol low-up of a patient with grade A CLL
The management of patients with early (stage A) CLL requires a
collaborative approach between primary and secondary care.
Some patients in stage A are regarded as having ‘‘smouldering
CLL’’, characterised by haemoglobin .13 g/dl, lymphocyte
count ,306109 cells/l, minimal or no lymphadenopathy and
a lymphocyte doubling time .12 months, and these patients
have a low progression rate (15% at 5 years, 80% 10-year
survival). By contrast, patients with stage B or C disease have a
40% 5-year survival and require early treatment.3
By extrapolation from the guidelines of the British
Committee for Standards in Haematology,1 patients with
indolent stage A CLL could be monitored in the primary care
setting with a FBC every 6 months for the first 2 years. If the
lymphocyte count doubles during this time, then the patient
should be referred to a haematologist for an assessment. For
patients whose lymphocyte count remains stable for this time,
there is a low likelihood of the disease progressing, and
monitoring can be reduced to an annual FBC. The follow-up of
the patients seen initially in hospital who do not require
treatment may be organised in primary care, in hospital
outpatients or through a home-care service, depending on local
resources and patient wishes. Before patients are discharged
from the hospital follow-up, a clear management plan should
be documented, which should include criteria for re-referral to
the haematology service.
UK GMS contract indicator: none.
When should I refer a patient with a low neutrophil
count?
Neutropenia is potentially associated with life-
threatening infection and we recommend that the
following situations are of significance and require
referral to secondary care:
Neutrophils ,16109 cells/l and the patient is unwell/febrile:
(especially if undergoing cancer chemotherapy): refer urgently
for admission.
Neutrophils ,16109 cells/l and the patient is well/afebrile:
repeat FBC with blood film examination within 48 h; if
neutropenia persists, refer for urgent haematology outpatient
department appointment.
Neutrophils 1–1.56109 cells/l and the patient is well: refer to
haematology or discuss with haematologist if neutropenia is
progressively severe or persists on two occasions at least
6 weeks apart; or refer to haematology or discuss with
haematologist if other blood count abnormality is present and
persistent on two occasions at least 6 weeks apart.
Neutropenia is classified as
N mild 1.0–1.56109 cells/l
N moderate 0.5–1.06109 cells/l
N severe ,0.56109 cells/l.4
Patients with neutrophil count ,16109 cells/l and fever
require urgent, parenteral, broad-spectrum antibiotics, as
infection may rapidly progress to established septic shock.
We found no published guidance for referral of patients with
mild neutropenia. This guidance is drawn from a consensus of
author and reviewer opinion.
Benign ethnic neutropenia is relatively common in indivi-
duals of African descent (neutrophil counts down to
16109 cells/l) and is also seen in some of Middle Eastern
extraction. Individuals are physically normal and lack a history
of susceptibility to infection. Confirm neutropenia with repeat
FBC and confirm normal morphology with blood film.4
Transient neutropenia not lasting.2 weeks is usually related
to viral infections and not associated with clinical problems.5
Occasionally, these infections may contribute to mild neutro-
penia for several months after the illness.
Most severe neutropenias are associated with fever, oral
ulceration, and bacterial or fungal infections.6 7 The following
areas should be reviewed:
History: Frequency and severity of infections, mouth ulcers,
recent viral illness, exposure to drugs and toxins, and
symptoms of malabsorption.4
Drugs: Excluding cancer chemotherapy, the highest-risk
categories are antithyroid drugs, trimethoprim–sulfamethoxa-
zole, sulfasalazine and neuropsychotropics. Many drugs may
cause a chronic mild neutropenia—for example, non-steroidal
anti-inflammatory drugs, sodium valproate (box 2).
Examination: Notably mouth ulcers, fever, signs of infection.
Investigations: Notably whether the full blood count is
otherwise normal.
Recurrent fever and oral ulcerations can be due to cyclical
neutropenia8: a rare autosomal dominant disorder in which
neutrophil counts oscillate between 0.16109 and 1.56109 cells/l
every 21 days. Neutropenic periods last 3–6 days, accompanied
by malaise, anorexia, fever, lymphadenopathy and mucosal
ulceration. The diagnosis is established by obtaining neutrophil
counts twice weekly for a minimum of 6 weeks, but this should
not hinder referral of severe neutropenia to secondary care.7
UK GMS contract indicator: none.
How should I interpret a raised eosinophil count?
We recommend the following if a patient’s eosinophil
count is (persistently) .0.356109 cells/l or
.1.56109 cells/l:
Clinical history concentrating on allergy/atopy, gastrointestinal,
skin, respiratory and joint symptoms, and any change in
general health (malignancy) combined, depending on clinical
context, with:
N blood film (to examine for any morphological abnormality of
the eosinophils),
N stool parasite examination
N urine analysis.
Non-specific allergy testing is not recommended
The upper limit of the reference range for the eosinophil
count is .0.356109 cells/l.10 Eosinophilia has been subdivided
into mild (0.35–1.5), moderate (1.5–5) and severe
(.5)6106 cells/l.11 In a review of 1862 cases studied in an
Italian series,12 the most common causes and frequencies
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(which include potential drug reactions in several categories)
can be summarised as follows:
N atopic diseases including asthma 79.7%
N parasitic infections 8.2%
N haematological neoplasia 2.4%
N allergic/atopic skin diseases 2.1%
N solid tumours 1.9%
N gastrointestinal disease 1.6% (mostly inflammatory bowel
disease and coeliac disease)
N lung disease 0.8%
N connective tissue diseases 0.6%.
These patients were identified from detailed clinical history,
and an escalating and extensive series of investigations were
performed until a diagnosis was established. A further 2.7% of
patients were defined as having eosinophilia of unknown
significance.
An additional group of patients has been identified with
idiopathic hypereosinophilic syndrome,13 which by definition
excludes all patients with eosinophilia for which a cause can be
found.14 A North American study of incidental eosinophilia15
(defined as eosinophil count of .5% or .0.76109 cells/l in this
study) in 195 300 automated haematology profiles found that
of the 225 cases (0.1% of samples), almost all were attributable
to either allergic processes or to known underlying diseases
(advanced malignancy, connective tissues disease). Only two
cases (patients receiving gold therapy) were both unanticipated
and not associated with signs or symptoms of the cause of the
eosinophilia. In 30% of cases, no cause was found by the
patient’s doctor, although these patients were not subject to
the same escalating investigations as in Rothenberg’s report.11
The authors concluded that repeat blood count and focused
investigations (parasitology, skin prick testing depending on
clinical context, foreign travel) are sufficient, and that
extensive diagnostic testing is unnecessary. Although the great
majority of cases will be attributable to common allergic or
parasitic disease, a small proportion potentially reflect other
serious lung, gastrointestinal, renal autoimmune or malignant
disease, although these would be expected to exhibit other
signs or symptoms of the disease. In addition, a small number
of patients will present with either the hypereosinophilia
syndrome or a haematological malignancy in which the only
feature may be eosinophilia. Therefore, it would be reasonable
to recommend that patients with persistent (.6 months) mild
eosinophilia or a finding of moderate or increasing eosinophilia
in which the above investigations do not reveal a cause should
be referred for immediate assessment. In patients with
moderate eosinophilia, if any signs of organ damage are
present, as indicated by cardiac or pulmonary symptoms, then
the referral should also not be delayed.
UK GMS contract indicator: none.
CARDIAC TROPONINS (POC AND RM)
Cardiac troponins are replacing conventional markers of
myocardial injury (creatine kinase and its isoenzymes, and
aspartate transaminase) as sensitive and specific markers of
injury. This answer examines the specific situation of patients
presenting to a general practitioner with chest pain, and not the
Box 1: Indications for treatment in chronic
lymphocytic leukaemia1
Progressive marrow failure: the development or worsening of
anaemia and/or thrombocytopenia
Massive (.10 cm) or progressive lymphadenopathy
Massive (.6 cm) or progressive splenomegaly
Progressive lymphocytosis
.50% increase over 2 months
Lymphocyte doubling time ,6 months
Systemic symptoms (It is important to exclude other causes for
these symptoms such as infection)
Weight loss .10% in previous 6 months
Fever .38 C˚ for >2 weeks
Extreme fatigue
Night sweats
Autoimmune cytopenias
Box 2: Drugs and chemicals associated with
neutropenia, excluding cytotoxic chemotherapy
(adapted from Moses9)
N Antimicrobials include penicillin, cephalosporins, vanco-
mycin, chloramphenicol, gentamycin, clindamycin, dox-
ycycline, flucytosine, nitrofurantoin, novobiocin,
minocycline, griseofulvin, lincomycin, metronidazole,
rifampin, isoniazid, streptomycin, thiacetazone, meben-
dazole, pyrimethamine, levamisole, ristocetin, sulfona-
mides, chloroquine, hydroxychloroquine, quinacrine,
ethambutol, dapsone, ciprofloxacin, trimethoprim, imi-
penem/cilastatin, zidovudine, fludarabine, acyclovir and
terbinafine.
N Analgesics and anti-inflammatory agents include amino-
pyrine, dipyrone, phenylbutazone, indomethacin, ibu-
profen, acetylsalicylic acid, diflunisal, sulindac, tolmetin,
benoxaprofen, barbiturates, mesalazine and quinine.
N Antipsychotics, antidepressants and neuropharmacologi-
cal agents include phenothiazines (chlorpromazine,
methylpromazine, mepazine, thioridazine, prochlorper-
azine, trifluoperazine, trimeprazine), clozapine, risper-
idone, imipramine, desipramine, diazepam,
chlordiazepoxide, amoxapine, meprobamate, thiothix-
ene and haloperidol.
N Anticonvulsants include valproic acid, phenytoin, tri-
methadione, Mesantoin, ethosuximide and carbamaze-
pine.
N Antithyroid drugs include thiouracil, propylthiouracil,
methimazole, carbimazole, potassium perchlorate and
thiocyanate.
N Cardiovascular drugs include procainamide, captopril,
aprindine, propranolol, hydralazine, methyldopa, quini-
dine, diazoxide, nifedipine, propafenone, ticlopidine
and vesnarinone.
N Antihistamines include cimetidine, ranitidine, tripelenna-
mine (Pyribenzamine), methaphenilene, thenalidine,
brompheniramine and mianserin.
N Miscellaneous drugs include allopurinol, colchicine,
aminoglutethimide, famotidine, bezafibrate, flutamide,
tamoxifen, penicillamine, retinoic acid, metoclopramide,
phenindione, dinitrophenol, ethacrynic acid, dichlorodi-
phenyltrichloroethane, cinchophen, antimony, pyrithyl-
dione, rauwolfia, ethanol, chlorpropamide, tolbutamide,
thiazides, spironolactone, methazolamide, acetazola-
mide, intravenous immunoglobulin and levodopa.
N Heavy metals include gold, arsenic and mercury.
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emergency-care hospital setting, and attempts to provide
guidance on when, if ever, this test may be appropriate in this
situation. Detailed guidance has been produced in the recent
NHS [National Health Service] Quality Improvement Scotland
Health Technology Assessment,16 which is used as the primary
reference source.
When should I measure cardiac troponin in someone
who comes to the surgery with chest pain?
We recommend that serum troponin should not be
measured in primary care, except in the following
possible situations:
N when admission to hospital would not be considered for
other medical reasons
N if a patient presents after a single episode of chest pain 24–
72 h previously, in order to establish whether myocardial
damage has occurred.
Myocardial infarction, or the acute coronary syndrome is a
clinical diagnosis, and measurement of cardiac troponin in
serum, although sensitive and specific for ACS, is only part of
that diagnosis.
Troponin is a component of the myocardial tissue that acts as
a molecular switch to regulate muscle contraction. Two
troponins of clinical interest, cardiac troponin T and cardiac
troponin I, are found only in the myocardium.17
Release of cardiac troponin T occurs on cardiac damage.
Measurement of cardiac troponin is the definitive biochemical
test for detection of myocardial infarction.18
Recent recommendations from the European Society of
Cardiology and the American College of Cardiology for the
definition of myocardial infarction stipulate that there must be
a rise and fall in troponin accompanied by either clinical
features suggestive of cardiac disease or changes in the ECG.18
Patients with recent (within 24 h) or recurrent acute chest
pain, that might be cardiac in nature will normally require
immediate emergency assessment. If the patient has episodes of
chest pain on exertion only, referral to a rapid-access chest pain
clinic may be considered more appropriate.
The only exception, where troponin measurement might be
considered, is if the patient has other medical problems that
mean that they would not wish to be sent to hospital. In this
case, measurement of cardiac troponin and an ECG 24 h after
the acute event can be used to confirm or exclude whether the
patient has had an ACS.
If a patient presents with a single episode of chest pain 24–
72 h previously, measurement of cardiac troponin and an ECG
will establish whether or not the chest pain was due to an ACS.
If the patient has had a myocardial infarction, he or she should
be referred urgently for cardiac review and for further
investigation. Whereas paradigms for care of patients with
ACS may change, the recent National Health Service Quality
Improvement Scotland Health Technology Assessment refers to
troponin testing only in the context of hospital care, and not in
a primary care setting.16
Any cause of cardiac damage, such as trauma (eg, traffic
accident, stabbing) myocarditis, or renal failure (where cardiac
death is common) will also result in increased troponin. Many
of secondary causes of cardiac damage have been observed that
can cause a troponin rise.19 In these situations, such rises are
associated with worse outcome.19
Some skeletal myopathies have cardiac as well as skeletal
muscle involvement. Measurement of cardiac troponin will
detect this. If creatine kinase is persistently increased in a
patient, measurement of cardiac troponin will establish
whether this has a cardiac component.
UK GMS contract indicator: none.
HIGH-DENSITY LIPOPROTEIN MEASUREMENT AND
TREATMENT
The high-density lipoprotein cholesterol (HDL-C) level is
inversely related to coronary risk, and is a necessary measure-
ment for the use of coronary risk calculation tables and
programs. Until recently, the emphasis on treatment targets has
been predicated on low-density lipoprotein cholesterol (LDL-C)
targets, although recent guidelines have highlighted the need to
consider intervening when HDL-C is low. These question-and-
answer sets examine indications for measuring HDL-C, and
consider when intervention may be appropriate.
This guidance should be read in conjunction with reviews 1
and 3 of this series, which consider monitoring other aspects of
cholesterol and triglyceride measurement,20 21 which are
accompanied by a further discussion in a case study on lipids
in a series of articles in the BMJ.22
When and how often should HDL-C be measured
together with total cholesterol and LDL-C?
We recommend that when assessing cardiovascular risk:
N HDL-C should be measured with total cholesterol, triglycer-
ides and LDL-C (an initial non-fasting sample is acceptable).
N If the non-fasting total cholestrol/HDL-C ratio is raised or the
patient is at high risk (.20% 10-year coronary heart disease
(CHD) risk), a fasting lipid profile should be obtained.
N Adult patients with diabetes should have an annual lipid
profile, including HDL-C level.
In patients receiving lipid-lowering treatment, HDL-C should
be measured:
N 8 (¡4) weeks after starting or changing any intervention to
raise HDL-C (lifestyle modification with or without drugs)
N annually thereafter in all patients receiving lipid-lowering
treatment.
Or as a minimum:
N Annually in patients with HDL-C ,1.3 or .1.7 mmol/l.
Large population studies have consistently demonstrated a
strong inverse relationship between plasma HDL-C and the risk
of CHD.
Low HDL-C levels may have a genetic cause and are also
associated with increased triglycerides, obesity and high
carbohydrate intakes (.60% of calories), physical inactivity,
type 2 diabetes, cigarette smoking and the use of certain drugs
(eg, b blockers, anabolic steroids and progestogens).23
Studies and drugs available to examine the benefit of
specifically treating low HDL-C levels in isolation are lacking.
Most treatment recommendations are aimed at achieving target
LDL-C levels for which there is convincing evidence of benefit.
Recent American24 and British25 26 guidelines do not include
specific recommendations on thresholds for initiating drug
treatment, on treatment goals and on monitoring intervals for
people with low HDL-C levels and varying levels of cardio-
vascular risk, but make reference to the need for practitioners to
be aware of the increased risk associated with low HDL in their
treatment decisions.
Screening
Measurement of HDL is essential to accurately assess absolute
cardiac risk and is necessary for the risk assessments
recommended by the UK National Service Framework26 and
Joint British Societies.25
HDL-C in the non-fasting state is lower by 5%–10% than in
the fasting state. Non-fasting measurements, therefore, slightly
overestimate CHD risk but are regarded as sufficiently accurate
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to use in screening and are more convenient for patients.27 All
people with abnormal non-fasting screening lipids or at high
risk should have a fasting lipid profile.25 26
The National Institute for Health and Clinical Excellence
recommends that all people with diabetes should have an
annual lipid profile (but makes no recommendations on the
management of low HDL-C).28
Monitoring interventions to raise HDL-C
No clear guidance is available on this topic. As any intervention
to raise HDL-C will normally run concurrently with other lipid
management, we recommend that HDL-C levels for people
undertaking interventions to raise HDL-C levels be maintained
at the same intervals as for people who are receiving treatment
to lower cholesterol and/or triglycerides—that is, 8 (¡4) weeks
after starting treatment and then every 8 (¡4) weeks until on
target.
Annual monitoring of patients receving lipid-lowering
treatment
The Joint British Societies’ guideline25 recommends that a full
lipid profile (ie, total cholesterol, HDL, triglyceride and
measured or calculated LDL-C) be performed annually in
patients receving lipid-lowering treatment. It could be argued
that repeated measurement of HDL-C is of limited benefit in
those in whom specific intervention would be intended, if the
total cholesterol adequately acts as a surrogate marker for LDL-
C. As a minimum, we would therefore suggest measurement of
HDL-C in patients in whom the total cholesterol figure may be
an inaccurate surrogate for LDL-C(see Smellie et al21 for a brief
review of calculated LDL-C) or in whom HDL-raising methods
might be considered. In the absence of specific guidance, this is
set arbitrarily at (1.2 (the potential intervention threshold in
women) and >1.7 (when the LDL may be lower than expected
as indicated by total cholesterol).
UK GMS contract indicator: none.
What is a low HDL-C and how can it be treated?
We recommend:
Low HDL can be considered as ,1.0 mmol/l in men and
,1.2 mmol/l in women.
Modification:
N Lifestyle modification as the first approach.
N Drug treatment to raise HDL-C levels may be considered,
once the target/lowest achievable LDL-C is reached, in
secondary and high-risk primary prevention (those whose
10-year cardiovascular risk exceeds 20%) if HDL-C remains
low despite lifestyle interventions.
Evidence suggests that the following lifestyle modifications
raise HDL-C levels, although there is limited clinical endpoint
evidence that can be related specifically to HDL-C:
N regular, brisk aerobic exercise for 30 min most days of the
week
N cessation of smoking
N weight loss for overweight and obese people
N moderate alcohol intake
N a diet rich in n-3 polyunsaturated fatty acids (oils, nuts,
cold-water fish and shellfish) with limited carbohydrates
that have a high glycaemic load.
A recent meta-analysis looking at the efficacy and safety of
HDL-C-increasing compounds (53 trials involving 16 802
people using fibrates and 30 trials involving 4749 people using
niacin) found that apart from flushes in the niacin group, both
fibrates and niacin were shown to be effective in increasing
HDL-C levels, well tolerated and safe,29 although the recent field
study did not show a large sustained increase in HDL-C.30
Prospective epidemiological studies have shown that an
increase in HDL-C of 0.1 mmol/l reduces the relative risk of a
coronary event by 2% in men and 3% in women.31
Most lipid management studies, however, have focused on
reducing LDL-C rather than raising HDL-C levels. A recently
published cohort study (18 815 people) estimated the effect of
changes in HDL-C adjusted for changes in total cholesterol on
cardiovascular events.32 It found that a rise in HDL-C by .20%
reduced the risk of a cardiovascular event in people taking lipid-
lowering treatment or who had been hospitalised previously for
cardiovascular disease (risk ratio (RR) 0.6; 95% CI 0.44 to 0.83).
However, it found no statistical relationship between HDL
change and cardiovascular outcome in people who had not
been hospitalised previously, or who were not taking lipid-
lowering treatment.
The National Cholesterol Education Program Expert Panel on
Detection, Evaluation, and Treatment of High Blood Cholesterol
in Adults (Adult Treatment Panel III)2 recommends that a low
HDL-C (,1.0 mmol/l) should receive clinical attention, but
does not recommend a specific treatment goal.
The National Service Framework26 and National Institute for
Health and Clinical Excellence28 guidelines make no specific
recommendations on the management of HDL-C, although the
recent Joint British Societies guideline refers to the need to
address other lipid abnormalities, including low HDL
(,1.0 mmol/l in men and 1.2 mmol/l in women).25
The Expert Group on HDL-C31 recommended a treatment goal
of >1.0 mmol/l for people with cardiovascular disease and
those without cardiovascular disease but at high risk, especially
those with type 2 diabetes or the metabolic syndrome.
Prescribers should be aware of the increased risk of
myopathy and rhabdomyolysis in patients treated with
fibrate–statin combinations, although absolute risk is low.
Specialist advice is recommended before combination treat-
ment in people who are (because of hypothyroidism, alcohol
misuse, existing myopathy).20
A recent consensus statement has also supported the
combined use of statin–nicotinic acid preparations as a useful
strategy to reduce CHD risk in patients with diabetes and the
metabolic syndrome.33
UK GMS contract indicator: none.
VIRAL DISEASES 2 (WI, WSAS, KGK)
These two questions consider the separate subjects of infectious
mononucleosis and rash in pregnancy. The first is complicated
by the availability of different tests, typically in two laboratory
disciplines (haematology and virology), and attempts to guide
the respective use of the tests in different clinical contexts. The
second has already been extensively researched in standard
operating procedures produced by the Health Protection Agency
Evaluations and Standards Laboratory, London, UK, and
restates much of the content of these. These standard operating
procedures are issued by the Standards Unit, Evaluations and
Standards Laboratory, Centre for Infections, Health Protection
Agency and are endorsed by the Health Protection Unit (UK),
the UK NHS, the National Public Health Service for Wales, the
UK Clinical Virology Network, the Association of Medical
Microbiologists, the UK Institute of Biomedical Scientists, the
Association of Clinical Microbiologists, the Scottish
Microbiology Association and the Welsh Microbiological
Association.
When should I investigate a patient for possible
infectious mononucleosis due to Epstein–Barr virus?
We recommend testing:
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N in febrile patients aged between 10 and 30 years with sore
throat, fatigue and splenomegaly, palatal petechiae, or
posterior cervical, axillary or inguinal lymphadenopathy34
N in younger or older patients:
N as an adjunct to the investigation of acutely raised
transaminases or haemolytic anaemia
N if infectious mononucleosis is strongly suspected clinically or
from contact history.
The term infectious mononucleosis is a syndromic diagnosis,
which can arise through a number of different aetiologies. The
most common cause is primary infection with Epstein–Barr
virus (EBV), but a clinically indistinguishable illness may arise
through primary cytomegalovirus (CMV), human herpesvirus-6
or toxoplasmosis infection. In addition, the acute seroconver-
sion illness after recent acquisition of HIV infection may bear
many similarities to infectious mononucleosis, and is often
described as a ‘‘glandular-fever-like illness’’.
Infectious mononucleosis is common in the 10–30-year age
band (6–8 per 1000 per year or higher in communities of
adolescents and young adults).35 It is rarer under the age of
10 years or over 30 years (,1 case per 1000 per year). Adults
are more likely to present with a hepatitic picture.36
No evidence-based guidelines were found and our recom-
mendations are summarised from a recent review,35 supported
by an earlier cohort study based on the at-risk population and
prevalence of symptoms.37 38
As the treatment of infectious mononucleosis is symptomatic
and the only direct management recommendation is avoidance
of contact sports,39 the main reason for investigating patients
would seem to be to confirm the cause of symptoms and
exclude other, more serious diseases, except in administrative
situations (eg, loss of work) if a specific diagnosis is desired.
The American Family Physician review35 also recommends
testing for group A b-haemolytic streptococcus concomitantly
in the above group of patients with febrile pharyngitis and
lymphadenopathy. This will be considered in a future question.
UK GMS contract indicator: none.
What tests should I use to investigate a patient for
possible infectious mononucleosis?
We recommend:
N FBC and differential count for lymphocytosis and atypical
lymphocytes
N heterophile antibodies (Monospot or similar) in immuno-
competent adults
N Viral serology in children ,12 years of age40 41 and in the
immunocompromised.
If a first heterophile antibody/FBC test is negative/not
supportive of infectious mononucleosis due to EBV:
N repeat test for heterophile antibodies in 5–7 days
N consider specific EBV viral serology (viral capsid antigen) if
rapid rule-out needed (eg, urgent return to sports desired).
If a second heterophile antibody test is negative and
confirmation of diagnosis is considered clinically important:
N Testing for CMV and toxoplasmosis is specifically recom-
mended only for pregnant women and in the immunocom-
promised
N Testing for HIV is recommended in at-risk patients.
The rigorous combined clinical and laboratory criteria
defined by Hoagland36 seem to be the most specific for
infectious mononucleosis but seem to lack sensitivity in clinical
practice.35 A positive result for heterophile antibody or .20%
atypical lymphocytes or .10% atypical lymphocytes with
lymphocyte count .50% of differential are considered strong
evidence of infectious mononucleosis, and no further testing is
recommended in an American review.35 However, false-nega-
tive rates may be 25% in week one of infection, falling to
approximately 5% in week three,36 and repeat testing is
recommended in suspected cases if an initial test is negative.
False-negative rates are also reported to be higher in children,40
in whom specific antibody testing is recommended,41 and in the
immunocompromised, in whom immunological testing is
considered potentially unreliable.41 The same UK guidance41
also recommends EBV-specific serology as preferable to
heterophile antibodies, although it describes the latter as
acceptable under (unspecified) clinical circumstances. Our
recommendation attempts to reconcile the UK and American
Family Physician recommendations for uncomplicated cases in
primary care.
Haematological complications, if present (eg, neutropenia,
haemolytic anaemia), will become apparent from the results of
the FBC, and will prompt further investigation by the
performing laboratory as indicated.
Specific antibodies to EBV viral capsid antigen are considered
better than heterophile antibodies in ruling out EBV infectious
mononucleosis, and are similar in their ability to rule in
infection42; they are recommended for use in patients with
typical symptoms and negative results for heterophile anti-
bodies, or where rapid rule-out is required (eg, for patients
wishing to return to sports). They develop slightly earlier than
heterophile antibodies. A negative result for IgM antibodies to
viral capsid antigen is considered strong evidence against
infectious mononucleosis. The IgM antibody is more specific for
acute infection and recommended as the test of choice in the
American Family Physician review.35 The IgG antibody persists
after infection. Specific testing strategies may vary between
laboratories, as no recommended standard was found.
Antibodies to the EBV nuclear antigen typically develop after
6–8 weeks and can be used to identify past, and, therefore,
non-acute, infection. Conversely, negative EBV nuclear antigen
with positive capsid IgM is suggestive of acute infection.
Other infections, such as acute CMV disease and toxoplas-
mosis, can produce clinical manifestations similar to EBV
infectious mononucleosis and may also be associated with
positive heterophile antibody tests. Nevertheless, it is unclear
whether there is any advantage in testing serologically for these
other infections except in the pregnant woman or in the
immunocompromised, as these diseases are usually self-limit-
ing and resolve with supportive therapy only. Specific guidance
on when to investigate for other causes seems to be lacking,
and we recommend at present that this be dictated by the
clinical need to establish a diagnosis. Similarly, testing for HIV
infection that presents initially as a mononucleosis-like illness
in recently infected patients (also known as the acute retroviral
syndrome) is indicated only if HIV infection is suspected
clinically and if testing is combined with appropriate patient
counselling.
UK GMS contract indicator: none.
What tests should I perform for a pregnant woman in
contact with a child with a macular rash?
We recommend:
N obtaining history of past rubella vaccination and testing for
rubella immunity
N sending serum sample to the laboratory with details of
pregnancy and contact, asking for erythrovirus (parvovirus)
B19 serology, and rubella serology if necessary
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N considering measles serology in patients arriving recently
from areas for measles.
The clinical problem here is that a pregnant woman in
contact with a non-vesicular rash illness may acquire either
rubella or erythrovirus (formerly known as parvovirus) B19
infection, both of which have potential deleterious conse-
quences for pregnancy.43 Maternal rubella virus infection in the
first 12 weeks of pregnancy carries a near 100% risk of the
congenital rubella syndrome in the developing fetus. Protean
manifestations of this are observed, the most common being
cataracts, congenital heart disease and central nervous system
abnormalities including sensorineural deafness. Maternal
rubella at 12–18 weeks of pregnancy is more likely to lead to
single organ damage, usually deafness. Maternal infection with
erythrovirus B19 results in an increased risk of spontaneous
miscarriage. If the pregnancy survives, maternal–fetal trans-
mission of infection may result in fetal heart failure, presenting
as hydrops fetalis (only described in maternal infections before
21 weeks of gestation). There is no congenital parvovirus
syndrome—that is, live babies born to mothers with documen-
ted gestational parvovirus infection do not have congenital
developmental abnormalities.
Rubella and erythrovirus B19 infection in the contact patient,
whether a child or an adult, may be clinically indistinguishable,
giving rise to non-specific macular rashes, and, in women
especially, arthralgia and even frank arthritis that may occur in
the absence of a rash. Fewer than half of the women with
parvovirus infection had rash or arthralgia.44 Both infections
should therefore be considered in any pregnant woman in
contact with a rash illness.
If a pregnant woman in contact with a child (or adult) with a
rash illness has had two previous rubella IgG-positive results on
record, two documented rubella immunisations, or one IgG-
positive result and one documented immunisation, she can be
regarded as immune to rubella and reassured that the risk of
rubella infection is remote. She should still be investigated for
possible erythrovirus B19 infection.44–46 If none of the above
obtains, she should be investigated for both rubella and
erythrovirus B19 infection. Note that should a rash develop in
the pregnant woman herself, she should be advised to seek
medical advice at once.
Laboratory investigation of rubella and erythrovirus B19
infections is by serological testing. Thus, a serum sample should
be sent to the laboratory, together with details of the stage of
pregnancy, the nature of the contact (particularly the time(s)
when the contact took place) and any past rubella IgG testing/
vaccination. The laboratory will test the serum for B19 IgG and
IgM, and, where indicated, rubella IgG and IgM.45–47 Further
action will depend on the results of these tests, which may
identify susceptibility to infection with, immunity to, or
evidence of recent infection with, one or both viruses. The
laboratory report should provide an interpretation of the
results, and clear guidance on the need for, and timing of,
further sampling and testing. Good communication between
the primary care physician (providing details of pregnancy and
contact) and the laboratory (providing interpretation of results
and guidance for further testing) is essential.
Although measles is rare in the UK, with increasing travel to
parts of the world where it is endemic and also an increase in
people arriving from countries where the disease is endemic,
this possibility should be considered in such people.
UK GMS contract indicator: none.
CONCLUSION
This seventh review brings to a running total of approximately
86 question-and-answer sets written to provide an overview of
current advice in the use of laboratory tests in primary care.
Answers to the first six question–answer sets can be found
elsewhere.20 21 48–51 The seven reviews have all used a common
search methodology,52 although where recent systematic
reviews have been performed, the guidance relies heavily also
on the findings of these reviews. Authors wishing to consult the
UK General Medical Services Contract and the current Quality
and Outcomes Framework guidance can find these on their
resective websites,53 54 along with the 2006 update.55
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